Prescription Required

Fast & Secure shipping on all orders

  • Quality & Safety Guarantee
  • Typically arrives within 3 – 5 Business days
Guaranteed Safe Checkout

What is Glyxambi?
(See detailed Medicine Prescription Information here)
Type of medication – Oral medication
Assist in – Regulating blood sugar.
Type – Prescription medication
Used for – Treat type 2 diabetes.
Medicine family – Gliptin family of diabetes drugs.
Dosage – Once daily, taken in the morning, with or without food
Glyxambi, the diabetic drug, contains linagliptin and empagliflozin as active components in it. Linagliptin is a member of the group of drugs known as dipeptidyl peptidase-4 enzyme inhibitors, whereas sodium-glucose co-transporter inhibitors include empagliflozin. Each tablet contains 10 mg or 25 mg of empagliflozin and 5 mg of linagliptin. The medication is a creation of the German-based, international pharmaceutical giant, Boehringer Ingelheim .

What is Type 2 Diabetes?
Condition where insufficient insulin is produced by body or abnormal responses to the insulin that their bodies produce are symptoms of type 2 diabetes. Pancreas produces and releases insulin in blood stream allowing blood sugar into the cells that your body for use as energy. When a person has type 2 diabetes, body cells become resistant to insulin. As a result, your body make more insulin to try to get cells to respond. This will lead to imbalance and your blood sugar will rise leading to type 2 diabetes. High blood sugar can cause serious health problems causing amputation or affecting your heart, vision, and kidneys.

What is it used for?
Our body has a group of gastrointestinal hormones called incretins. Incretins help production of insulin as and when body requires it for example after eating and also incretins reduce the production of glucagon by the liver as and when it is not needed for example during digestion. Dipeptidyl peptidase-4 (DPP-4) can damage incretins and body may not regulate blood glucose levels. Linagliptin is a class of gliptins, an oral diabetes that protect incretins from damage and are known as DDP-4 inhibitors. Gliptins help regulate blood glucose levels. Linagliptins are usually prescribed for people with type 2 diabetes who have not responded well to drugs such as metformin and sulphonylureas.
DPP-4 inhibitors may help with weight loss besides decreasing blood sugar levels. They have also been linked with higher rates of pancreatitis.
Other medicines in class of gliptins are:

  • Januvia (Sitagliptin)
  • Galvus (Vildagliptin)
  • Onglyza (Saxagliptin)
  • Tradjenta (Linagliptin)
  • Glyxambi

DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), which include Glyxambi, are a broad class of anti-diabetic medications that help you control your insulin levels, particularly after a meal when blood sugar levels are high. Additionally, it aids in reducing the quantity of sugar your body produces on its own.
Glyxambi, contains both linagliptin and empagliflozin, is recommended as an adjuvant therapy for diabetic patients to help them better control their blood glucose levels. This drug should be combined with lifestyle changes including exercise and dietary changes for the greatest outcomes. Empagliflozin is typically used for adult patients who have type II diabetes mellitus and cardiovascular disease to lower their risk of cardiovascular death. Patients with type I diabetes or diabetic ketoacidosis should not take this medication.

How to take this medication
Take the medication in the morning each day with or without food. For best treatment results, patients should adhere to advice by health care person for food and exercise. Patients who forget to take a dose of Glyxambi should do so as soon as they recollect. When the next dose is almost due, they should omit the missed dose and take the subsequent dose as prescribed. Under no circumstances should patients take the medication twice as often. While Glyxambi can be used in conjunction with other diabetic drugs, there is an increased risk of hypoglycemia (low blood glucose) when doing so.

How does this drug work?
The active ingredients of Glyxambi (empagliflozin and linagliptin) work synergistically to enhance glycemic control in diabetes patients. As was already noted, linagliptin is known to inhibit dipeptidyl peptidase-4 (DPP-4) enzymes, whereas empagliflozin is an inhibitor of the sodium-glucose co-transporter (SGLT2). The primary transporter responsible for reabsorbing glucose from the glomerular filtrate is sodium-glucose co-transporter 2. Empagliflozin lowers the renal threshold for glucose via inhibiting SGLT2, which lowers the renal threshold for glucose and raises the excretion of glucose through the urine. Dipeptidyl peptidase-4 is inhibited by linagliptin, on the other hand. DPP-4 is an enzyme that breaks down the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) (GLP-1). Linagliptin helps increase the concentration of active incretin hormones while promoting the insulin release in a glucose-dependent manner. at the same time, it decreases the level of glucagon in the blood circulation.


  • Renal function should be assessed by doctor before initiating medication
  • Glyxambi, the diabetic drug, contains linagliptin and empagliflozin as active components in it. There are two different strength of tablets available
    • 10 mg empagliflozin/5 mg linagliptin
    • 25 mg empagliflozin/5 mg linagliptin
  • The recommended dose of GLYXAMBI is 10 mg empagliflozin and 5 mg linagliptin once daily, taken in the morning, with or without food.
  • Dose may be increased to 25 mg empagliflozin and 5 mg linagliptinonce daily

Glyxambi side effects

  • Runny nose
  • Stuffy nose
  • Upper respiratory tract infections
  • Sore throat

Please be aware that not all Glyxambi side effects may be listed in this section. Patients may experience adverse effects not included on this list. Patients should consult a doctor right away if their symptoms worsen or continue to persist. Patients should seek medical assistance as soon as any major adverse effects appear.